Locally advanced breast cancer in octogenarian women.
Elderly patients are more likely to present with locally advanced breast cancer than younger patients. Furthermore, due to the accelerated aging of the western population, the incidence of breast cancer in this population is expected to steadily rise in the coming decades. So far, no guidelines are available for the management of octogenarian patients presenting with inoperable disease, what frequently results in a dilemma for the treating physician. For the time being, these patients should be ideally treated within the context of a clinical trial. In all other cases, the treatment has to be individualised, frequently based on data extrapolated from different population of patients, or retrospective series. This article reviews the current evidence, options, and most promising approaches for these patients.
Mano
Max
M
Beatson Oncology Centre, Glasgow, UK. max.mano@northglasgow.scot.nhs.uk
Fraser
Ghislaine
G
McIlroy
Pauline
P
Stirling
Lynne
L
MacKay
Helen
H
Ritchie
Diana
D
Canney
Peter
P
D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000451:nursing / Q000628:therapy; D005260:Female; D016330:Frail Elderly; D015577:Geriatric Assessment; D006801:Humans; D018719:Erb-b2 Receptor Tyrosine Kinases; D043823:Taxoids / Q000627:therapeutic use; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018931:Antineoplastic Agents, Hormonal; D018719:Erb-b2 Receptor Tyrosine Kinases; D043823:Taxoids; D000068878:Trastuzumab